Kala Bio Inc.
KALA
Market Cap$29.81M
Close$
$0.50
90.2% downside
Current Fair Value
90.2% downsideOvervalued by 90.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $29.81 Million |
|---|---|
| Enterprise Value | $6.29 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-1.01 |
| Beta | -1.98 |
| Outstanding Shares | 6,345,869 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -0.82 |
|---|---|
| PEG | 3.39 |
| Price to Sales | - |
| Price to Book Ratio | 1.28 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.17 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 2.97 |
| Debt to Equity | 3.28 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Kala Pharmaceuticals Inc
CEO: Mark Iwicki